Abstract
Olaparib is used to treat BReast CAncer susceptibility protein (BRCA)-associated, platinum-sensitive ovarian cancer. Olaparib inhibits poly(ADP-ribose) polymerase, thereby blocking the repair of single-strand DNA breaks. This results in synthetic lethality in BRCA-associated cancer cells, which have a dysfunction of another DNA repair pathway - homologous recombination.
© 2015 The British Pharmacological Society.
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
DNA Repair / drug effects
-
Humans
-
Neoplasms / drug therapy*
-
Phthalazines / adverse effects
-
Phthalazines / pharmacology
-
Phthalazines / therapeutic use*
-
Piperazines / adverse effects
-
Piperazines / pharmacology
-
Piperazines / therapeutic use*
-
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
Substances
-
Antineoplastic Agents
-
Phthalazines
-
Piperazines
-
Poly(ADP-ribose) Polymerase Inhibitors
-
olaparib